Abstract: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel disease (IBD) and methods of treating enterobacterial infections using anti-flagellin antibodies in humans, other animals and birds.

Abstract: Use of mixed mode chromatography for purification of an antibody from an antibody mixture, for example) a Pichia pastoris fermentation mixture containing impurities such as host cell proteins and DNA is described Mixed mode chromatography is used instead of protein A chromatography and presents certain advantages over protein A chromatography Furthermore, the integration of such a method into a multi-step procedure with other fractionation methods for purification of antibodies suitable for in vivo applications is provided.

Abstract: Described are human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from Enterococcus.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.

Abstract: The present invention relates to monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a, including pathogenic species such as the methyciline-resistant Staphylococcus Aureus (MRSA), coagulase-negative Staphilococcus, Staphylococcus sciuri and Enterococcus, and any other bacteria containing the PBP2-a protein or homologous sequences. The invention also relates to the use of the monoclonal antibodies capable of recognising and binding to the PBP2-a protein and to other proteins having sequences homologous to PBP2-a in a complementary immunodiagnostic test for detecting resistance to beta-lactam antibiotics.

Abstract: An isolated human Apolipoprotein L-I corresponding to a wild type human Apolipoprotein sequence is modified by a deletion at its C-terminal end.

Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract: The invention concerns antibodies or fragments thereof that are directed against a Staphylococcus aureus epitope.

Abstract: Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.

Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.

Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody can be a monoclonal antibody having both an antigen-binding portion that binds at least one bacterial antigen and a constant region that does not bind staphylococcal protein A.

Abstract: An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immuno-logic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.

Abstract: Various specific meningococcal proteins are disclosed. The invention provides related polypeptides, nucleic acids, antibodies and methods. These can all be used in medicine for treating or preventing disease and/or infection caused by meningococcus, such as bacterial meningitis.

Abstract: The present invention provides an antibody which binds to B. anthracis with toxin, formulations for administration of such antibodies intramuscularly, and methods of administering such antibodies prophylactically or therapeutically.

Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.

Abstract: Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention provides PBP2a peptide antigens for generating antibodies against MRSA, and provides high-affinity binding agents that detect MRSA by selective immunoreactivity with PBP2a. The antibodies are useful in methods and systems for detecting MRSA, including biosensor systems, or as components of diagnostic or detection kits. The antibodies, in some embodiments, have therapeutic value against MRSA infection.

Abstract: The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter.

Abstract: The present invention relates to materials and methods for prevention, treatment and diagnosing of infections caused by Helicobacter pylori (H. pylori). More specifically the present invention relates to new specific variable antibody regions, derivatives thereof and the fully human immunoglobulin, Abba3, which exhibit specific activity to the BabA antigen, expressed by H. pylori, methods for the production of said immunoglobulins, their isolation and use, for example in detection of disease causing H. pylori. The present invention also relates to immunization therapies, i.e. passive vaccination for the treatment and prevention of pathologic infections caused by H. pylori strains.

Abstract: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or tetraplegic individuals.

Abstract: The invention relates to isolated or purified bacterial adhesin conformers, preferably with improved stability and/or immunogenicity. In a preferred aspect, the invention comprises an isolated bacterial adhesin conformer F. Also provided are methods of isolation and/or separation of such adhesin conformers. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other bacterial antigens to provide therapeutic compositions with broader range.

Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.

Abstract: The present invention is directed to diagnostic tools and therapies using antibodies to Bacillus anthracis. Specifically, the present invention is directed to a B. anthracis-specific monoclonal antibody that binds to the EA1 antigen (corresponding to the eag gene) of the S-layer (surface layer) of spores. This monoclonal antibody may be used in a variety of applications, including to specifically detect and diagnose B. anthracis. Preferably, antibodies are monoclonal and bind to a surface protein, such as EA1 protein, on the spores of B. anthracis, and not to spores of either B. cereus or B. thuringiensis. Antibodies can be incorporated into detection kits using, for example, colloidal particle based lateral flow detection system. Such detection kits can distinguish anthrax spores from non-pathogenic varieties of spores. In addition, the invention is directed to B.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

Abstract: The present invention relates to an isolated antigen from Streptomyces coelicolor that is useful for developing, inter alia, vaccines against pathogenic bacteria of humans and animals. The present invention also relates to vaccines and antibodies developed using the isolated antigen. The present invention also relates to methods of using the antigen, vaccines, and antibodies of the present invention to detect, treat, and prevent infection and diseases associated with pathogenic bacteria.

Abstract: The purpose of the present invention is to provide a method and an agent to efficiently inhibit the function of the drug efflux pump of Pseudomonas aeruginosa. The invention provides a method to inhibit the function of the drug efflux pump of Pseudomonas aeruginosa, comprising modifying any amino acid residue selected from 100th to 109th or 311th to 320th amino acid residues in the amino acid sequence of mature OprM protein. The invention also provides an agent having such inhibitory effect, and a screening method thereof.

Abstract: The present invention relates to antigenic polypeptides expressed by pathogenic microbes, including antigenic polypeptides encoded by the nucleic acid sequence of FIG. 1, vaccines comprising the antigenic polypeptides and therapeutic antibodies directed to the antigenic polypeptides.

Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: Provided is an effective means for therapy of infection, particularly infection with Pseudomonas aeruginosa. Provided are a monoclonal antibody against PcrV or a part thereof, and a pharmaceutical composition containing the same as an active ingredient. Concretely, monoclonal antibody of the present invention has excellent inhibiting activity on cytotoxicity with respect to a target cell of Pseudomonas aeruginosa. Also, the monoclonal antibody of the present invention has high affinity with PcrV.

Abstract: The present invention relates to the field of animal health and in particular to Lawsonia intracellularis. In particular, the invention relates to a method of diagnosing Lawsonia intracellularis infection and a diagnostic test kit using Lawsonia intracellularis-specific antibodies. The invention also relates to the use of the method or test kit for diagnosing Lawsonia intracellularis infections.

Abstract: According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in Staphylococcus aureus, a method and a kit for detecting the toxin with the use of the antibody, and a pharmaceutical composition containing an antibody against a Panton-Valentine leukocidin toxin for treating PVL infection caused by Staphylococcus aureus containing PVL are provided. Also, an antibody which is capable of binding to Panton-Valentine leukocidin F and has no cross-reactivity to LukD and/or HlgB and an antibody which is capable of binding to Panton-Valentine leukocidin S and has no cross-reactivity to at least one of LukE, HlgC, and HlgA are provided.

Abstract: Disclosed is a monoclonal antibody having very high affinity to anthrax toxin and potent toxin-neutralizing activity. Also disclosed are a composition for neutralizing anthrax toxin comprising the antibody and a kit for detecting anthrax toxin.

Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.

Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.

Abstract: A method for stimulating the immune response to a vaccine applied to a mammalian subject includes the step of administering to the subject an effective amount of EtxB or a molecule having substantially equivalent activity, free from whole toxin and not linked to an antigen.

Abstract: A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian Borrelia infections.

Abstract: Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.

Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.

Abstract: The present invention relates to antibodies and related molecules that specifically bind to protective antigen of Bacillus anthracis (PA). Such antibodies have uses, for example, in the prevention and treatment of anthrax and anthrax toxin poisoning. The invention also relates to nucleic acid molecules encoding anti-PA antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same.

Abstract: Disclosed are EspFU (EspF-like polypeptide encoded by a gene of the cryptic prophage CP-933U of enterohemorrhagic E. coli) polypeptides, fragments thereof, nucleic acids that encode EspFU polypeptides, or fragments thereof, and cells including the polypeptides, fragments, and/or nucleic acids. Also disclosed are model systems, kits, and methods for screening that use, for example, EspFU polypeptides and nucleic acids. Also included are pharmaceutical and diagnostic compositions and methods of diagnosis and treatment of EHEC infections.

Abstract: Disclosed is a prophylactic or therapeutic agent for bacterial infectious diseases, which comprises an antibody capable of binding to a toxin or an antitoxin that constitutes a bacterial toxin-antitoxin system to inhibit the interaction between the toxin and the antitoxin or a gene for the antibody as an active ingredient.

Abstract: Antibodies for binding epitopes of BoNT/A and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting BoNT/A in a sample and/or in a method for purifying BoNT/A from an impure solution. In addition, the antibodies can be used for passive immunization against BoNT/A intoxication or as intoxication therapy. Another aspect of the invention is a kit for detecting BoNT/A in a sample.